SOST and osteoporosis: Sclerostin, encoded by SOST, is an established osteoporosis drug target with the sclerostin antibody romosozumab showing anti-fracture efficacy in a Phase 3 clinical trial.29 NOTUM is a potential osteoporosis drug target.